Clinical Trial Update: Pembrolizumab (MK-3475) in MM Patients With Residual Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of pembrolizumab (MK-3475) in multiple myeloma patients with residual disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: PETHEMA Foundation | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED